Does the Presence of IgG Mean Current or Past Infection?

IgG antibodies on their own do not reliably tell you whether an infection is happening right now or happened months ago. After most infections, the immune system begins producing IgG within about a week or two and then keeps producing it, sometimes for years or even decades. A positive IgG result is a sign that your immune system has encountered a particular pathogen at some point, but pinning down when requires additional testing and clinical context that a single IgG reading cannot provide.

Why IgG Shows Up During Both Active and Past Infections

When your immune system first meets a new pathogen, it initially produces IgM antibodies. Fairly quickly after that, B cells undergo a process called class switch recombination, where they shift from making IgM to making IgG, IgA, or IgE. This switch improves the immune system’s ability to clear the specific pathogen that triggered the response.¹ Once that switch happens, IgG levels climb during the active infection, peak, and then gradually decline. But they rarely vanish entirely. Long-lived plasma cells and memory B cells continue to produce low levels of IgG for months, years, or sometimes a lifetime.

This timeline is the core of the confusion. During the first SARS outbreak, for instance, IgG appeared as early as four days after symptoms began, peaked around day fifteen, and persisted at high levels for over three months.² That means a blood draw at day ten and a blood draw at day ninety could both come back IgG-positive, even though the infection cleared weeks earlier. A single snapshot tells you exposure happened. It does not tell you when.

Paired Samples and the Four-Fold Rise

The oldest and most straightforward workaround is to draw two blood samples several weeks apart. If IgG levels rise by four-fold or more between the first (acute) sample and the second (convalescent) sample, that strongly suggests a current or very recent infection. If IgG is present at similar levels in both samples without a significant increase, the interpretation shifts toward a past exposure. This approach is a standard part of the WHO diagnostic criteria for infections like chikungunya: patients with stable IgG across paired samples collected at least three weeks apart are classified as having had a previous exposure, not an active infection.³

The drawback is obvious: you need two blood draws separated by weeks. That delay is acceptable in epidemiological surveillance but often impractical in a clinic where someone needs a treatment decision now. It also assumes the patient comes back for the second draw, which is far from guaranteed.

IgG Avidity Testing

A faster alternative to paired samples is the IgG avidity test. Avidity refers to how tightly an antibody binds to its target. Early in an infection, freshly minted IgG antibodies bind loosely, meaning they have low avidity. Over the following weeks and months, the immune system fine-tunes those antibodies through a process called affinity maturation, producing IgG that grips the pathogen’s proteins much more firmly. High-avidity IgG therefore points toward an older, resolved infection, while low-avidity IgG suggests the infection is recent.

This distinction matters enormously in certain clinical situations. For toxoplasmosis and cytomegalovirus, where a primary infection during pregnancy carries serious risks to the fetus, combined IgG/IgM testing followed by IgG avidity testing is considered crucial for determining when the infection occurred.⁴ Finding high-avidity IgG in a pregnant woman who also tests IgM-positive can be enormously reassuring, because it suggests the infection happened before pregnancy rather than during it.

Avidity testing has also been applied to dengue, where distinguishing a first infection from a second one has clinical implications for disease severity. In one evaluation, an IgG avidity test correctly classified 55 of 57 patients as having either a primary or secondary dengue infection.⁵ And for Lyme disease, where persistent IgG after successful treatment is common and diagnostically confusing, researchers have been developing avidity tests based on specific antigen targets. Early work on the C6 segment of VlsE has shown that anti-C6 IgG avidity changes in ways consistent with fundamental immunology, suggesting it could eventually serve as a supplementary tool to separate past from active infection.⁶

IgG Subclasses Can Hint at Timing

Not all IgG is the same. There are four subclasses, IgG1 through IgG4, and they do not all appear on the same schedule. In toxoplasmosis, IgG1 and IgG3 are the first to appear after initial infection, with IgG1 remaining dominant throughout both acute and chronic stages.⁷ In parvovirus B19 infection, IgG3 shows up during the acute phase and then fades, while IgG4 does not appear until months later. Researchers found that the ratio of IgG3 to IgG4 against a specific viral protein could distinguish recent from remote parvovirus B19 infection with a sensitivity and specificity both around 97 to 98 percent.⁸

Subclass profiling is not routinely available in most clinical labs, and the pattern varies by pathogen, so this is not a universal diagnostic tool. But it illustrates that there is more information packed into an IgG result than a simple positive-or-negative readout captures. When standard testing leaves the timing ambiguous, subclass analysis is one more layer of evidence that specialists can reach for.

When IgG Persists for Years After Successful Treatment

Some infections leave behind IgG signatures that last far longer than you might expect. Lyme disease is a prime example and a frequent source of diagnostic confusion. After successful antibiotic treatment for Lyme, IgG levels decline slowly. In one long-term follow-up, more than half of patients developed negative IgG readings within five years of therapy, but some still tested positive nine to ten years later.⁹ The authors emphasized that a single sample showing antibodies against the Lyme bacterium must always be carefully evaluated alongside clinical symptoms, because the antibodies can persist long after the infection is gone.

A separate study looking at patients ten to twenty years after active Lyme disease found that a quarter of those who had had early Lyme disease still had IgG reactivity, and among those who had had Lyme arthritis, the figure was 62 percent. The researchers concluded explicitly that these persistent antibody responses are not indicative of active infection.¹⁰ This is exactly the kind of scenario that generates anxiety for patients: they feel fine, their doctor treated them years ago, yet a lab result still comes back positive. Without proper context, that result can lead to unnecessary retreatment.

Cross-Reactivity Between Related Pathogens

IgG does not always bind exclusively to the pathogen that originally triggered its production. Closely related organisms can share enough surface structure that antibodies trained against one will latch onto another, producing a false positive. This cross-reactivity is a well-known headache with flaviviruses, a family that includes dengue, Zika, West Nile, Japanese encephalitis, and tick-borne encephalitis. When sera from patients with confirmed dengue infections were tested against Zika virus, every sample showed cross-reactive binding, and nearly half of the dengue-specific monoclonal antibodies tested also bound to whole Zika virus particles.¹¹

In practical terms, this means a person who had dengue years ago could test IgG-positive for Zika without ever having been exposed to it. A study testing sera from dengue patients found that nine of sixteen samples were IgG-positive for tick-borne encephalitis virus, and seven were IgM-positive for at least one other flavivirus, using standard antibody tests.¹² Neutralization tests, which measure whether antibodies can actually block a specific virus from infecting cells, are more specific but also more labor-intensive and less widely available. For anyone living in or traveling through regions where multiple flaviviruses circulate, IgG results need to be interpreted with an awareness that the antibody may be responding to a different member of the family.

IgG That Was Never Yours to Begin With

Two situations can put IgG into your blood that has nothing to do with your own immune response to an infection. Both can produce misleading serology.

The first is maternal transfer. IgG is the only antibody class that crosses the placenta efficiently, so newborns arrive with a supply of their mother’s IgG. These maternal antibodies are detectable in infants for months. An individual-participant meta-analysis of diphtheria, tetanus, and pertussis antibodies found half-lives ranging from roughly 29 to 35 days, depending on the specific antigen.¹³ For IgG1 specifically, one study estimated an average half-life of about 48 days, with roughly 17 percent of the original maternal IgG1 still measurable at four months and about 7 percent at six months.¹⁴ Maternal HPV antibodies follow a similar timeline, remaining detectable in offspring for about six months.¹⁵ Any IgG testing in a young infant has to account for the possibility that the antibodies are the mother’s, not evidence that the baby has been infected.

The second is intravenous immunoglobulin (IVIG) therapy, where pooled IgG from thousands of donors is infused into patients with immune deficiencies or autoimmune conditions. Because these donor pools come from populations with widespread exposure to common pathogens, IVIG carries antibodies against many infections the recipient has never had. A case report highlighted false-positive results for CMV after IVIG administration, with the risk of unnecessary follow-up testing and investigations.¹⁶ A prospective study of seven patients found that each person gained between two and five new positive serology results after IVIG, including false positives for Epstein-Barr virus, herpes simplex, West Nile virus, CMV, and the fungi that cause histoplasmosis and coccidioidomycosis. The effect was strongest at higher cumulative doses.¹⁷ If your doctor does not know you recently received IVIG, a positive IgG test for one of these infections could send everyone down the wrong diagnostic path.

Polyclonal Activation and Other Serological Noise

Some infections trigger a broad, non-specific stimulation of B cells, causing the immune system to churn out antibodies against all sorts of targets, not just the pathogen responsible for the current illness. Epstein-Barr virus is a well-known offender. During acute EBV infection, the resulting polyclonal B-cell activation can produce heterophile antibodies that cross-react with unrelated tests, including treponemal assays for syphilis.¹⁸ Someone with acute mono could get a false-positive syphilis result, which is clearly a problem if the result is taken at face value without considering the clinical picture.

A separate issue is the prozone effect, where paradoxically high concentrations of antibodies can actually cause a test to read as negative. In one assay used for transplant matching, sera with very high antibody levels gave negative results when tested undiluted but showed strongly positive results after being diluted 1:10.¹⁹ While this particular example involved HLA antibodies rather than infection-specific IgG, the principle applies across immunoassay platforms: extremely high antibody concentrations can saturate the test system and produce a falsely low or falsely negative result. It is a rare scenario, but it illustrates that serological testing has failure modes in both directions.

When IgG Never Appears at All

On the opposite end, some people with confirmed infections never produce detectable IgG. This phenomenon, sometimes called sero-silence, affects an estimated 5 to 8 percent of people after a PCR-confirmed SARS-CoV-2 infection, depending on the test used and the population studied.²⁰ A negative IgG result in these individuals would incorrectly suggest they were never infected.

Immune status shapes how quickly IgG rises and falls. In severe COVID-19 patients, those with higher body mass had higher IgG levels and took longer to lose detectable antibodies, while immunocompromised patients had lower IgG levels and lost them faster.²¹ This means the same IgG test can carry different clinical implications depending on who is being tested. An immunocompromised person who tests IgG-negative months after a known infection may simply have lost their antibodies sooner, not escaped infection.

Latent viral infections can also influence how long IgG from other exposures sticks around. A ten-year follow-up of Swedish children found that carrying Epstein-Barr virus accelerated the decline of measles and rubella vaccine-induced IgG, while CMV carriage was associated with a slower decline in rubella-specific IgG.²² The background infections a person carries can shape how durable their IgG responses to other exposures are, adding yet another variable to the interpretation of a single test result.

Vaccination Versus Infection

Modern vaccines deliberately generate IgG responses, which creates a practical question: if someone tests IgG-positive, is that from the vaccine or from an actual infection? During the COVID-19 pandemic, laboratories addressed this by testing for antibodies against different viral proteins. Most mRNA vaccines targeted only the spike protein, so IgG against the nucleocapsid protein suggested true infection rather than vaccination. This distinction helped healthcare systems track actual infections among vaccinated populations.²³

The picture differs for mucosal immunity. Natural SARS-CoV-2 infection triggers IgA in saliva and the airways in addition to serum IgG, while vaccination primarily raises serum IgG without boosting specific salivary IgA. IgG from vaccination can be found in saliva, but only when blood levels are high.²⁴ This is one reason infections and vaccines produce somewhat different patterns of protection, and it means that measuring only serum IgG gives an incomplete picture of someone’s immune status regardless of whether the IgG came from a needle or a natural encounter.

When Serology and Direct Detection Disagree

Clinicians often combine IgG serology with direct pathogen-detection methods like PCR. The two tests answer different questions. PCR asks “is the pathogen’s genetic material present right now?” while serology asks “has the immune system responded to this pathogen?” The clinical sensitivity of each test changes over the course of an infection: PCR is most useful early, when viral load is high, while antibody tests become more useful later, after the immune system has had time to mount a response.²⁵

There is a window in the middle of many infections where both tests can be positive simultaneously, and a later window where only antibodies remain detectable. In the early COVID-19 pandemic, a study of healthcare workers found individuals who tested negative on PCR but positive for both IgM and IgG, including neutralizing antibodies, consistent with acute infection that PCR missed. Many of these individuals had symptoms and known contact with confirmed cases.²³ Serology filled a gap that PCR alone left open, but the interpretation still required clinical judgment about what the positive IgG actually meant in each patient’s context.

None of these tests are self-interpreting. A positive IgG is a data point, not a diagnosis. Whether it reflects an infection that is happening now, one that resolved months ago, one that was treated years ago but left behind an immunological footprint, cross-reactivity from a related pathogen, maternal antibodies, or even pooled donor antibodies from a recent IVIG infusion depends on everything the lab cannot see: the patient’s symptoms, their exposure history, their immune status, and the specific biology of the pathogen in question. The test answers one narrow question about what is floating in the blood; the rest is medicine.